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Abstract
ET-743 (trabectedin; Yondelis) is approved in Europe for the treatment of soft tissue sarcomas. Emerging phase 1
and 2 clinical data have shown high response rates in myxoid liposarcoma in part owing to the inhibition of the
FUS-CHOP transcription factor. In this report, we show that modulation of specific oncogenic transcription factors
by ET-743 may extend to other tumor types. We demonstrate that, among a panel of pediatric sarcomas, Ewing
sarcoma family of tumors (ESFTs) cell lines bearing the EWS-FLI1 transcription factor are the most sensitive to treat-
ment with ET-743 compared with osteosarcoma, rhabdomyosarcoma, and synovial sarcoma. We show that ET-743
reverses a gene signature of induced downstream targets of EWS-FLI1 in two different ESFT cell lines (P = .001). In
addition, ET-743 directly suppresses the promoter activity of a known EWS-FLI1 downstream target NR0B1 lucifer-
ase reporter construct without changing the activity of a constitutively active control in ESFT cells. Furthermore, the
effect is specific to EWS-FLI1, as forced expression of EWS-FLI1 in a cell type that normally lacks this fusion protein,
HT1080 cells, induces the same NR0B1 promoter, but this activation is completely blocked by ET-743 treatment.
Finally, we used gene set enrichment analysis to confirm that other mechanisms of ET-743 are active in ESFT cells.
These results suggest a particular role for ET-743 in the treatment of translocation-positive tumors. In addition, the
modulation of EWS-FLI1 makes it a novel targeting agent for ESFT and suggests that further development of this
compound for the treatment of ESFT is warranted.
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Introduction
The Ewing sarcoma family of tumors (ESFTs) is the second most com-
mon malignant bone tumor of childhood [1]. The hallmark of the dis-
ease is the characteristic chromosomal translocation involving the EWS
gene and one of the members of the ets family of transcription factors,
most commonly FLI1 [2]. This translocation fuses the DNA binding
domain of FLI1 with the transactivating domain of EWS, leading to a
dysregulated transcription factor that alters the expression of more than
500 genes [2–6].
Downstream targets of EWS-FLI1 have been shown to mediate on-
cogenic transformation [7], regulate the cell cycle [8,9], and participate
in the evasion of apoptosis [10,11] and cellular senescence [12]. Fur-
thermore, a number of groups have shown that decreasing the ex-
pression of EWS-FLI1 by antisense DNA or small interfering RNA
methods decreases the proliferation of ESFT cells in vitro and decreases
tumorigenicity in orthotopic mouse models (reviewed in Maksimenko
and Malvy [13]). Therefore, agents that modulate EWS-FLI1 would
be of clinical interest.
ET-743 (trabectedin; Yondelis) is a natural product isolated from
the sea squirt Ecteinascidia turbinata [14,15]. This drug has shown
cytotoxicity in a variety of histologic cell types, and recent clinical stud-
ies have led to approval in Europe for the treatment of soft tissue
sarcomas. Specifically, phase 1 and 2 data show high response rates in
myxoid liposarcoma, which is known to have the t(12;16)(q13;p11)
chromosomal translocation that generates the FUS-CHOP fusion
protein [16–22].
Recently, it has been shown that ET-743 blocks DNA binding of
the oncogenic transcription factor FUS-CHOP and reverses the tran-
scriptional program in myxoid liposarcoma. By reversing the genetic
program created by this transcription factor, ET-743 promotes differ-
entiation and reverses the oncogenic phenotype in these cells [23].
Other than transcriptional interference, the mechanism of action of
ET-743 is complex and not completely understood. The compound
is known to bind and alkylate DNA at the N2 position of guanine.
It is known from in vitro work that this binding occurs in the minor
groove, spans approximately 3 to 5 bp and is most efficient with CGG
sequences [24]. Additional favorable binding sequences are TGG,
AGC, or GGC [24,25]. Once bound, this reversible covalent adduct
bends DNA toward the major groove [26], interferes directly with
activated transcription [27,28], poisons the transcription-coupled
nucleotide excision repair (TCR) complex [29–31], promotes degrada-
tion of RNA polymerase II [32], and generates DNA double-strand
breaks [33,34].
Although a considerable amount of mechanistic work has been done
with ET-743, it is not known what determines preferential sensitivity to
the drug in the clinic. Furthermore, it is not known if other specific
oncogenic transcription factors could be targeted by ET-743 or if this
targeting could provide another mechanism of cytotoxicity that is
additive with other known mechanisms of action.
In this report, we hypothesized that ET-743 may interfere with the
transcriptional program of EWS-FLI1 at the promoter level similar
to FUS-CHOP in myxoid liposarcoma. We based this hypothesis
on several factors including the fact that FUS and EWS are family
members. We show that ET-743 does in fact reverse a gene signature
of EWS-FLI1 and heightened sensitivity is observed in vitro relative to
other pediatric sarcomas that lack the EWS-FLI1 transcription factor.
In addition, we demonstrate specific suppression of a downstream
target promoter both in a native and artificial context. Finally, we
show preservation of other previously described mechanisms of action
in ESFT and the potent induction of apoptosis at nanomolar concen-
trations in ESFT cells.
Materials and Methods
Cell Culture
ESFT cells TC32, TC71, and 5838 have been described and char-
acterized previously [35]. The presence of the EWS-FLI1 transcription
factor was routinely confirmed by reverse transcription–polymerase
chain reaction (PCR). The rhabdomyosarcoma cell line RD and the
osteosarcoma cell lines HOS, SaOS, and U2OS were obtained from
American Type Culture Collection (Rockville, MD). The RH30 and
EW8 cells were gifts from Dr P. Houghton. SCS991 synovial sarcoma
was patient-derived, and the SYT-SSX2 translocation was confirmed
by reverse transcription–PCR. Cells were cultured in RPMI-1640
(Gibco, Invitrogen, Carlsbad, CA) containing 10% fetal bovine serum
(Sigma, St Louis, MO) and supplemented with penicillin/streptomy-
cin and L-glutamine to a final concentration of 100 U/ml, 100 μg/ml,
and 2 mM, respectively.
Cell Proliferation Assays
Cells were plated to a density of 3000 to 5000 cells per well and al-
lowed to recover overnight. They were subsequently treated with ET-
743 dissolved in 1% DMSO and diluted to the given concentration
maintaining the final concentration of DMSO at less than 0.0001%.
To measure the cell number, 20 μl of CellTiter 96 (Promega, Madison,
WI) was added to a volume of 100 μl of medium and allowed to incu-
bate at 37°C for 2 hours. The color change of thewell wasmeasuredwith
a 96-well plate reader and plotted against a standard curve to determine
the cell number. All treatments were done in replicates of three to six.
Luciferase Assays
TheNR0B1 promoter was PCR-amplified from genomicDNAusing
5′GGTACCGTCCTAGAACTTCCAGAAG3′ as the forward primer
and 5′GCTAGCCTTCGCTCATAAGCATG-3′ as the reverse primer,
containing the restriction sites KpnI and NheI, respectively. The insert
was cloned into theTOPO-TA shuttle vector (Invitrogen), subsequently
digested using KpnI and NheI restriction enzymes, and ligated into the
PGL 4.18 vector (Promega). The plasmid was linearized with SalI and
cloned into TC32 cells using O-017 program and buffer R as per the
Amaxa nucleofection protocol. Single-cell clones were grown under se-
lective pressure using G418 at a final concentration of 0.5 mg/ml.
The CMV promoter was PCR-amplified from PGL 4.75 plasmid
DNA (Promega) and cloned into PGL 4.18 using the In-Fusion system
(Clontech, Mountain View, CA). Primers were designed with a 15-bp
overlap using online software with the 5′ACCTAGCTCGCTAGCGG-
CTAACTGGCTCAATA3′ forward primer and the 5′TATCCTCGAG-
GCTAGCCCACTGACTGCGTTAGCAAT 3′ reverse primer. After
PCR amplification, the insert was combined with plasmid in a 2:1 ratio
as per the manufacturer’s instructions. The purified plasmid was nucleo-
fected into TC32 cells, and single-cell clones were expanded as previously
mentioned. All plasmids were sequenced to confirm the construct.
Luciferase assays were performed using Steady-Glo (Promega) pro-
longed signal luciferin. Cells were incubated with drug for the desig-
nated time. One hundred microliters of Steady-Glo was subsequently
added to the cells. The cells were disrupted and allowed to equilibrate
at room temperature for 5 to 10 minutes before measuring the bio-
luminescent signal on the Victor3 multilabel counter (Perkin Elmer,
Waltham, MA).
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Preparation of HT1080 Cell Lines That Express EWS-FLI1
EWS-FLI1 was cloned from Ewing cells and packaged into a lentiviral
vector. The lentiviral particles of EWS-FLI1 and GFP were prepared by
Betty Conde at the NCI Frederick and titered to a final density of at least
1 × 106 infectious units per milliliter. The viral supernatant was added to
the HT1080 cells in the absence of antibiotics with a multiplicity of in-
fection of at least 10 in the presence of 6 μg/ml polybreen. The cells were
allowed to recover overnight and subsequently batch-selected under se-
lective pressure with blasticidin at a final concentration of 10 μg/ml.
Preparation of HT1080 Reporter Cell Lines
The NR0B1 promoter luciferase construct (described previously) was
cloned into the transgenic EWS-FLI1 expressing HT1080 cells using
nucleofection with the Amaxa system as per the manufacturer’s instruc-
tions. The CMV promoter construct (described previously) was also
nucleofected using the identical conditions. The cells were subsequently
batch selected using G418 at a final concentration of 0.5 mg/ml.
Western Blot Analysis
TC32 and TC71 cells were plated and allowed to recover overnight.
The cells were treated with ET-743 at 10 and 1 nM for 12 hours and
subsequently scraped into PBS. The cells were lysed using LDS lysis
buffer (Sigma), and the protein was quantitated by using a BCA color-
imetric assay (Pierce, Thermo-Scientific, Rockford, IL). After loading on
a NuPage 4% to 12% gradient gel (Invitrogen), the lysates were trans-
ferred to nitrocellulose using the iBlot system (Invitrogen). The blots were
probedwith 2μg/mlmouse anti-FLI1 (BDPharmingen, SanDiego, CA)
and secondary (1:1000) antimouse (Cell Signaling, Danvers, MA). The
poly (ADP-ribose) polymerase antibody (Cell Signaling) was used in a
dilution of 1:1000. The bands were visualized on film using ECL detec-
tion reagent (Amersham, GE Healthcare, Little Chalfont, UK).
Microarray Analysis of Downstream Targets
TC32 and TC71 cells were plated in parallel and allowed to recover
overnight. The cells were treated with ET-743 at a final concentration
of 10 nM and allowed to incubate for 12 hours. The medium was
aspirated, and the cells were washed with PBS. RNAwas collected using
TRIzol (Invitrogen) and the RNeasy kit (Qiagen, Germantown, MD)
as per standard methods. RNA integrity was confirmed by using the
bio-analyzer (Agilent, Santa Clara, CA) according to standard methods.
Gene expression profiling was performed using the Affymetrix Gene-
Chip Human Genome U133 Plus 2.0 microarray. RNA was in vitro
transcribed, fragmented, hybridized, and stained using the appropriate
Affymetrix GeneChip kits as per the manufacturer’s instructions. The
.CEL files were exported from Affymetrix GCOS software and normal-
ized with RMAketch from Affymetrix Power Tools. The gene set en-
richment analysis (GSEA) method (http://www.broad.mit.edu/gsea/)
[36] was applied to investigate the enrichment of EWS-FLI down-
stream targets. GSEA analysis was completed with a weighted enrich-
ment statistic, and genes were ranked using log2 ratio of expressions
between ET-743–treated cells and control.
Results
ESFT Cells Are More Sensitive to ET-743 Treatment than
Other Pediatric Sarcoma Cell Lines
To test our hypothesis that EWS-FLI1 inhibition by ET-743 adds an
additional mechanism of toxicity specific to ESFT cells, we looked at
the relative sensitivity of ESFT compared with other pediatric sarcoma
cell lines that lack the EWS-FLI1 transcription factor. We treated a
series of cell lines representing ESFT, osteosarcoma, embryonal rhabdo-
myosarcoma, alveolar rhabdomyosarcoma, and synovial sarcoma with
ET-743. The ESFT cell lines were the most sensitive to 1 nM ET-743
at 48 hours, demonstrating greater than 50% inhibition of proliferation
at this concentration (Figure 1A). In comparison, all osteosarcoma cell
lines evaluated showed a less than 10% inhibition at the identical time
and concentration.
Interestingly, 5838 was the least sensitive of the four ESFT cell lines
tested. This cell line harbors the EWS-ERG translocation, whereas
TC32, TC71, and EW8 all are characterized by the EWS-FLI1 trans-
location. It is known that all ets transcription factors share the same
GGA(A/T) core binding domain [37], but it is not clear beyond the
core sequence what additional sequence requirements exist.
It is also interesting to note that the alveolar rhabdomyosarcoma cell
line RH30 was more sensitive than the embryonal cell line RD. RH30
cells contain the PAX3-FKHR translocation. FKHR belongs to the
same winged helix turn helix family of DNA binding transcription fac-
tors as FLI1, although the binding motifs are different [3,38]. Taken
together, the data demonstrated greater sensitivity of ESFT containing
EWS-FLI1, all with subnanomolar half-maximal inhibitory concentra-
tion (IC50) values, compared with other sarcoma cell lines (Figure 1B),
and suggest that the antiproliferative effect may be connected to the
EWS-FLI1 transcription factor.
ET-743 Induces Apoptosis and Decreases the Expression
of Multiple EWS-FLI1 Downstream Targets
To investigate whether the heightened sensitivity of ESFT cells to
ET-743 is related to suppression of the EWS-FLI1 transcriptional pro-
gram, we looked at the effects of ET-743 on gene expression in ESFT
cells in two different cell lines, TC32 and TC71. We used GSEA to
determine whether suppression of the gene signature of EWS-FLI1
occurs with ET-743 treatment [36]. GSEA allows one to determine
the placement of a set of genes on a second rank-ordered gene list. In
this case, we treated cells with ET-743, evaluated the changes in gene
expression using Affymetrix microarrays, and ranked the genes from the
most induced with treatment to the most suppressed. We then looked
for the placement of a list of published downstream targets that are
induced by EWS-FLI1 on this list [5]. We found most genes clustered
on the suppressed side of the gene list with an overall statistically sig-
nificant suppression of the gene signature of EWS-FLI1 with ET-743
treatment (P < .001; Figure 2A). Of the 61 genes evaluated, 49 (80%)
showed decreased expression. There was very little induction of genes
that are suppressed by EWS-FLI1 (data not shown).
This effect could not be accounted for by nonspecific cytotoxicity be-
cause there were a large number of genes induced with treatment and no
apoptosis observed at the 12-hour time point and 10-nM concentration
tested as shown byWestern blot (Figure 2B). Furthermore, if there were
no relationship between treatment and this gene set, these genes would
randomly distribute on the rank-ordered list and not generate a statisti-
cally significant effect. Finally, there was a potent induction of apoptosis
as demonstrated by an increase in cleaved poly (ADP-ribose) polymerase
that followed this suppression at 24 hours that would be expected with
suppression of EWS-FLI1 (Figure 2C ).
ET-743 Inhibits the Promoter Activity of the EWS-FLI1
Target Gene NR0B1
To further investigate whether the enhanced ET-743 effect in
ESFT cells is due to the inhibition of EWS-FLI1 activity, we designed
Neoplasia Vol. 13, No. 2, 2011 ET-743 and EWS-FLI1 Activity in Ewing Sarcoma Grohar et al. 147
a luciferase reporter construct that uses the promoter of a well-
characterized EWS-FLI1 downstream target, NR0B1, to drive the ex-
pression of luciferase. The luciferase activity of these cells was measured
relative to a constitutively active CMV-driven luciferase to control for
nonspecific transcriptional inhibition or a cytotoxic reduction in lucif-
erase expression.
Because knockdown of EWS-FLI1 is lethal to cells, the best time
point to evaluate the luciferase reporter construct is at a time before cell
death. Therefore, we evaluated the luciferase expression of the NR0B1
reporter and CMV control after 12 hours of exposure to ET-743. Treat-
ment of TC32 cells containing the NR0B1 luciferase construct with
ET-743 resulted in a marked dose-dependent inhibition of luciferase
activity of between 50% and 80% at 12 hours (Figure 3A). There
was very little inhibition observed in the CMV-driven luciferase at
the same time and concentrations tested (Figure 3A). This inhibition
occurred in the nanomolar range, and this suggests direct modulation
of the EWS-FLI1 transcription factor by ET-743. It should be noted
that this effect is not due to the nonspecific cytotoxicity (Figure 3B).
Furthermore, prolonged exposure of ESFT cells to ET-743 demon-
strates the same effect at concentrations closer to the IC50 when the
data are expressed normalized to cell number (Figure 3, C and D).
ET-743 Blocks the Activation of the NR0B1 Promoter That
Occurs with Forced Expression of EWS-FLI1 in HT1080 Cells
To determine whether the modulation of EWS-FLI1 is specific to
this transcription factor, we expressed EWS-FLI1 in the non–EWS-
FLI1–bearing HT1080 fibrosarcoma cell line and subsequently evalu-
ated the effect of ET-743 treatment on the NR0B1 and CMV luciferase
reporter constructs (Figure 4A). After confirming that transduction of
the HA-tagged EWS-FLI1 in the HT1080 cells was stable by Western
blot analysis (Figure 4B), we showed that EWS-FLI1 increases the
activation of the NR0B1 promoter by 40% relative to the GFP trans-
duction control (P = .0008; Figure 4C). Treatment of these cells with
ET-743, however, completely blocks this activation at concentrations as
low as 10 nM in a dose-dependent fashion (P = .00005; Figure 4C).
The suppressive effect could not be accounted for by a decrease in cell
number, as no statistically significant difference in viability was found
between treatment and controls because the cells were once again eval-
uated at a 12-hour time point before an effect on viability occurs (data
not shown). In contrast, the CMV promoter–driven luciferase demon-
strated high-level expression typical of a constitutively active promoter
construct, but no change in bioluminescence was observed relative to
the GFP control with forced expression of EWS-FLI1 (Figure 4D). In
addition, no interference with expression of luciferase was observed
with ET-743 treatment in this constitutively active CMV-driven re-
porter construct (Figure 4D).
GSEA Confirms Previously Reported Mechanisms of Action
of ET-743 and Demonstrates Induction of Genes
Involved in Apoptosis
Next, we investigated similarities between the gene signature altered
by ET-743 in ESFT cells and published curated gene sets. The Broad
Institute maintains a database of more than 1890 microarray experi-
ments (http://www.broad.mit.edu/gsea/) [36]. The analysis looks for
similarities in expression between the target gene set (ET-743 treatment
of ESFT cells) and any of the 1890 gene sets and reports the size (num-
ber of genes that overlap) as well as the statistical similarity both as a
P value and a false discovery rate (FDR; Tables W1 and W2). The
top 11 gene sets identified after sorting the list for size and maintaining
P < .001 and FDR < 0.03 are shown in Table 1.
A number of gene sets that represent DNA damage were identified
using these criteria. Most notably, data sets generated by treating nor-
mal human epidermal keratinocyte cells with UVB or either UVB or
Figure 1. Ewing sarcoma cell lines that contain the EWS-FLI1 transcription factor are particularly sensitive to ET-743 treatment. (A) TC71,
TC32, and EW8 show a 60% to 75% inhibition of proliferation relative to solvent control when treated with ET-743 at a concentration of
1 nM for 48 hours. All other sarcoma cell lines show a more modest inhibitory effect. (B) IC50 values for the various cell lines treated with
ET-743. The 5838 cell line showed a plateau effect at approximately 53% and therefore the IC50 could not be determined (UTD).
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Figure 2. ET-743 decreases the expression of the downstream targets of EWS-FLI1 without changing the expression of the EWS-FLI1
transcription factor. (A) Enrichment plot showing an EWS-FLI1 activated gene set obtained from a published meta-analysis [5]. ET-743
reverses EWS-FLI1–activated genes in a statistically significant manner (P < .001). The curve shows the running sum of enrichment
score (ES) for ranked proteins. The vertical line specifies the maximum ES score. The genes listed under the plot are the leading edge
subset. (B) Western blot demonstrates no change in expression of EWS-FLI1 in two different ESFT sarcoma cell lines TC32 and TC71
when treated with ET-743 for 12 and 24 hours. There is minimal apoptosis observed at 12 hours as evidence by minimal cleaved PARP.
By 24 hours, significant apoptosis has occurred at both 10 and 1 nM. β-Actin confirms equal loading of protein lysate (C).
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UVC treatment of fibroblasts taken from patients with xeroderma
pigmentosa, trichothiodystrophy, or Cockayne syndrome [39] were
found to be statistically significant. Interestingly, a similar comparative
analysis done of a Cockayne syndrome gene set identified considerable
overlap with ET-743 gene signatures [40]. We also identified gene sets
that suggest a relationship with differentiation (HSC_Mature_adult
[41]) and chromatin remodeling (Table 1).
In addition, there was overlap in our expression data with a curated
list of genes that reflect ET-743–sensitive sarcoma cell lines that in-
cluded one ESFT and four myxoid liposarcoma cell lines (ET743_
Sarcoma_DN) [42]. It is notable that a number of curated gene sets
that represent data generated by treating other cell types with ET-743
were not identified including a set of genes from ET-743–resistant sar-
coma cell lines as well as chondrosarcoma cells and ovarian carcinoma
cells that were profiled after selecting for resistance to ET-743.
Discussion
ET-743 is a natural product isolated from the marine sea squirt
E. turbinata. This compound exhibits a strong cytotoxic effect in a
variety of cancer cell types of both epithelial and mesenchymal origin.
The broad cytotoxic profile likely stems from ET-743’s primary mech-
anism of action of alkylating the N2 position of guanine at selective
sequences [24,25], which in turn poisons TCR [29–31] and inhibits
the transcription of specific gene sets [23,27,28].
Despite the broad range of cytotoxicity, the clinical trials of ET-743
have revealed some preferential activity against sarcomas most notably
myxoid liposarcoma, a tumor characterized by the FUS-CHOP onco-
genic transcription factor [16–22]. Recently, it was shown that ET-743
directly interferes with the FUS-CHOP–mediated block in differenti-
ation in myxoid liposarcoma [23]. It has been suggested that release
from this differentiation block explains the selective sensitivity of this
tumor type to ET-743 in the clinic. However, it is not known what, if
any, other tumors bearing fusion transcription factors might be par-
ticularly sensitive to the drug.
In this report, we demonstrate that the sensitivity of ESFT cells to
ET-743 is associated with the modulation of EWS-FLI1 activity. We
show that ESFT cells are more sensitive than other pediatric sarcoma
cell lines and that this sensitivity correlates with the modulation of an
Figure 3. ET-743 selectively modulates the expression of the EWS-FLI1 downstream target promoter NR0B1 luciferase construct. (A)
Luciferase activity is markedly decreased with 10 nM ET-743 treatment at 12 hours in cells that contain the NR0B1 promoter construct
(P= .006). A dose-dependent effect is observed with almost 50% inhibition of luciferase in the 5-nM sample (P= .01). No effect is observed
at the identical 5-nM concentration and time with the CMV promoter construct. Data are normalized to the solvent control. (B) There is a
minimal effect on cell viability at the time and concentration tested. (C, D) The inhibition of luciferase in the NR0B1 promoter luciferase
construct (P = .004) but not the CMV is observed at similar concentrations as the IC50 after a longer 24-hour exposure. In this case, the
data are expressed normalized to the cell number to account for the nonspecific decrease in luciferase expression caused by cell death.
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EWS-FLI1 regulated promoter. In addition, this effect can be reca-
pitulated in a different cellular context by transducing a fibrosarcoma
cell line with EWS-FLI1 leading to a strong induction of the NR0B1
promoter that is completely blocked with ET-743 treatment.
Finally, we show that the level of expression of EWS-FLI1 does not
change, but the expression of a gene signature of induced downstream
targets of EWS-FLI1 is reversed and leads in part to the subsequent
induction of apoptosis. The reversal of the EWS-FLI1 gene signature
would not be expected for a general transcription inhibitor, and in-
stead, this suggests a relationship between this gene signature and
the cellular response to drug treatment. In addition, the luciferase data
that use a CMV-driven control further argue against a general mecha-
nism of global transcription inhibition.
It is not clear if the gene signature reversal demonstrated by GSEA
stems from a direct block in DNA binding of EWS-FLI1 similar to
what has been reported for FUS-CHOP [23] or some other indirect
mechanism. The luciferase reporter studies suggest that the effect oc-
curs at the level of the downstream target promoter. This mechanism is
plausible given the overlapping binding domains of EWS-FLI1 and
ET-743. The original report that characterized the DNA binding do-
main of FLI1 used an epitope tagging strategy coupled with in vitro
selection to determine the optimal FLI1 binding sequence. The report
identifies a consensus FLI1 binding sequence of ACCGGAAG/aT/c
and shows a greater sequence dependence on nucleotides 5′ to the
GGAA core than other ets transcription factors. In addition, changing
the nucleotide immediately 5′ to the core from a C to an A blocks
Figure 4. EWS-FLI1 activates the NR0B1 promoter with forced expression of EWS-FLI1 in the HT1080 cell line that normally lacks the
fusion. ET-743 interferes with the activation of NR0B1 in this HT1080 cell line that expresses EWS-FLI1. (A) Schematic showing HT1080
transduction experiment. (B) Western blot confirming the presence of the EWS-FLI1 oncogene in the HT1080 cells. The Western blot
also shows TC32 lysate as a control. EWS-FLI1 in the HT1080 cells is slightly shifted because it contains an HA-tag. (C) HT1080 cells that
contain EWS-FLI1 activate the NR0B1 promoter by 40% more than baseline with forced expression of EWS-FLI1 (P = .0008). However,
treatment of the cells with 10 nM ET-743 returns this activation to baseline (P = .00005). (D) The CMV-driven luciferase shows high-level
luciferase activity that does not change either with the introduction of EWS-FLI1 or with ET-743 treatment. All luciferase data are ex-
pressed as normalized to the solvent control.
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FLI1 binding [3]. This is significant because the preferred binding
domain of ET-743 is CGG, whereas AGG is disfavored. Therefore,
a CGGAA sequence would exactly overlap the preferred binding se-
quence of ET-743, interrupt EWS-FLI1 binding, and account for
the results presented in this report.
Consistent with this notion is the finding that the ESFT cell line
5838 containing the EWS-ERG translocation is less sensitive to
ET-743 than those ESFT cell lines that have an EWS-FLI1 translo-
cation. Recently, an ERG consensus sequence was identified to be
(A/G)(G/C)AGGAA(A/G) and was not activated by FLI1 suggesting
some but not complete overlap of these ets transcription factor family
members activities [43]. In addition, The ERG ets transcription fac-
tor binding domain features an A immediately 5′ to the GGAA core
and therefore does not have a preferred ET-743 binding site over-
lapping its binding domain [43]. Work continues to definitively dem-
onstrate a change in the chromatin binding of EWS-FLI1 in the
presence of ET-743. To date, our chromatin immunoprecipitation ex-
periments have not been of sufficient quality to definitively demon-
strate a mechanism, and we continue to pursue alternative strategies
aimed at determining the effect of ET-743 on EWS-FLI1 binding to
native chromatin.
Nevertheless, the similarities of myxoid liposarcoma and ESFT tran-
scription factor dynamics most likely contribute to the sensitivity to
ET-743 in these two tumor types. Both cells have a dependence on
their transcriptional program for maintenance of the oncogenic pheno-
type. In addition, EWS-FLI1 and FUS-CHOP share overlapping DNA
binding domains with ET-743, although the sequences are different.
EWS-FLI1 and ET-743 share the CGG binding domains in the coding
strand, whereas the complementary strand of the CCAAT FUS-CHOP
binding domain contains an ET-743 TGG binding sequence. Likely
the overlapping binding domains coupled with the inherent depen-
dence of these two cell types on the corresponding transcriptional sig-
natures is additive with the well described mechanisms of ET-743 and
explains the heightened sensitivity of these cells to ET-743.
Finally, an analysis of the GSEA enrichment data provides further
evidence that the effects of EWS-FLI1 inhibition are additive with
the other well characterized mechanisms in ESFT cells. Most notably,
gene sets generated by UVB or UVC treatment of fibroblasts taken
from patients with xeroderma pigmentosa, trichothiodystrophy, or
Cockayne syndrome [39] were identified as similar to ET-743 treat-
ment of ESFT cells. Patients with xeroderma pigmentosa, trichothio-
dystrophy, and Cockayne syndrome are born with a defect in TCR.
Therefore, our finding that treatment of ESFT cells with ET-743
leads to global gene changes similar to UV damage in patients with
defective TCR suggests that this mechanism of generating UV-like
damage and poisoning TCR is active in ESFT cells.
Finally, one would hypothesize that the reversal of activity of an
oncogenic transcription factor would lead to chromatin remodeling
and release from a block in differentiation similar to what has been de-
scribed for FUS-CHOP and myxoid liposarcoma [23]. Work continues
to investigate whether this is the case in ESFT cells; however, our GSEA
identified gene sets that were statistically similar to ET-743 treatment of
ESFT cells and involved chromatin remodeling and a release of a block
in differentiation in other cell types.
In summary, ESFTs have been shown to be particularly sensitive to
ET-743 in vitro, and there are some data supporting its activity in the
clinic [20]. We hypothesize that the reversal of the genetic program
created by the oncogenic transcription factor likely provides an ad-
ditional mechanism of cytotoxicity that is additive to the known
mechanisms of cytotoxicity of ET-743 in ESFT. It is not clear if this
effect is based on a direct block of EWS-FLI1 binding or an indirect
mechanism. A detailed genome-wide chromatin structure study would
be required to answer this question. Nevertheless, the demonstrated
modulation of activity of EWS-FLI1 coupled with early clinical trial
results suggests that further development of ET-743 in ESFT is war-
ranted. In addition, a heightened sensitivity for translocation-positive
tumors based on the blockade of their associated oncogenic transcrip-
tion factor with ET-743 treatment is suggested, and a close examina-
tion of the effects of ET-743 on a variety of oncogenic transcription
factors may identify other important targets.
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Table W1. Suppressed Gene Sets That Overlap with the Genes That Suppressed with ET-743
Treatment in ESFT Cells.
Name Size NOM, P FDR, q
UVC_XPCS_ALL_DN 478 <.001 0.0000
UVC_XPCS_8HR_DN 408 <.001 0.0000
DIAB_NEPH_DN 374 <.001 0.0155
UVC_TTD_ALL_DN 358 <.001 0.0000
HSC_MATURE_ADULT 331 <.001 0.0238
UVC_TTD_4HR_DN 297 <.001 0.0000
UVB_NHEK1_DN 270 <.001 0.0000
ET743_SARCOMA_DN 269 <.001 0.0271
UVC_XPCS_4HR_DN 242 <.001 0.0000
BAF57_BT549_UP 238 <.001 0.0002
HDACI_COLON_SUL_DN 215 <.001 0.0202
VENTRICLES_UP 205 <.001 0.0258
HSA04810_REGULATION_OF_ACTIN_CYTOSKELETON 198 <.001 0.0315
HSA04510_FOCAL_ADHESION 194 <.001 0.0100
GH_GHRHR_KO_24HRS_DN 172 <.001 0.0050
UVC_TTD_8HR_DN 165 <.001 0.0000
OLD_FIBRO_DN 158 <.001 0.0202
BRCA_BRCA1_NEG 154 <.001 0.0218
UVC_TTD-XPCS_COMMON_DN 144 <.001 0.0000
BRENTANI_PROTEIN_MODIFICATION 143 <.001 0.0104
GH_GHRHR_KO_24HRS_UP 142 <.001 0.0199
CALCIUM_REGULATION_IN_CARDIAC_CELLS 140 <.001 0.0318
HSA04530_TIGHT_JUNCTION 132 <.001 0.0063
UVB_NHEK1_C6 130 <.001 0.0000
HSA04360_AXON_GUIDANCE 128 <.001 0.0038
GH_AUTOCRINE_DN 122 <.001 0.0039
HSA01030_GLYCAN_STRUCTURES_BIOSYNTHESIS_1 111 <.001 0.0362
G_PROTEIN_SIGNALING 90 <.001 0.0070
PHOSPHATIDYLINOSITOL_SIGNALING_SYSTEM 88 <.001 0.0002
BRCA1KO_MEF_DN 79 <.001 0.0209
ST_INTEGRIN_SIGNALING_PATHWAY 78 <.001 0.0054
CREB_BRAIN_8WKS_UP 75 <.001 0.0042
HSA04520_ADHERENS_JUNCTION 75 <.001 0.0157
HSA04664_FC_EPSILON_RI_SIGNALING_PATHWAY 74 <.001 0.0283
CARIES_PULP_DN 70 <.001 0.0299
HSA04720_LONG_TERM_POTENTIATION 69 <.001 0.0052
UVB_NHEK3_C8 66 <.001 0.0002
UVC_LOW_ALL_DN 58 <.001 0.0000
OLDONLY_FIBRO_DN 53 <.001 0.0092
NFATPATHWAY 52 <.001 0.0006
HDACI_COLON_CUR_DN 49 <.001 0.0002
ET743PT650_COLONCA_DN 44 <.001 0.0000
NOVA2_KO_SPLICING 42 <.001 0.0019
CMV_HCMV_TIMECOURSE_14HRS_DN 41 <.001 0.0089
BIOPEPTIDESPATHWAY 38 <.001 0.0002
DFOSB_BRAIN_2WKS_UP 38 <.001 0.0010
UVB_NHEK3_C5 35 <.001 0.0000
AT1RPATHWAY 34 <.001 0.0068
GLYCOGEN_METABOLISM 34 <.001 0.0159
HSA00970_AMINOACYL_TRNA_BIOSYNTHESIS 31 <.001 0.0071
HDACPATHWAY 30 <.001 0.0002
CREBPATHWAY 27 <.001 0.0007
HDACI_COLON_CUR24HRS_DN 25 <.001 0.0069
The microarray data generated by treating TC32 and TC71 with ET-743 was compared with more
than 1892 curated gene sets using GSEA [36]. All had P < .001 and FDR < 0.05.
The source of the data can be found on the Web site (http://www.broad.mit.edu/gsea/) and is
referenced in the text where appropriate.
Shaded data indicate data sets discussed in the text.
Size indicates the number of genes in the gene set that shows overlap with the ones in the expres-
sion data set.
Table W2. Induced Gene Sets That Showed Significant Overlap.
Name Size NOM, P FDR, q
CMV_HCMV_TIMECOURSE_ALL_UP 464 <.001 0.0393
REOVIRUS_HEK293_UP 236 <.001 0.0053
CARIES_PULP_UP 205 <.001 0.0085
UVB_NHEK1_UP 173 <.001 0.0006
CMV-UV_HCMV_6HRS_UP 120 <.001 0.0054
BLEO_HUMAN_LYMPH_HIGH_24HRS_UP 92 <.001 0.0008
LVAD_HEARTFAILURE_UP 89 <.001 0.0025
UVB_NHEK3_C0 82 <.001 0.0017
HYPOXIA_REVIEW 81 <.001 0.0125
UVC_TTD_ALL_UP 76 <.001 0.0000
DNMT1_KO_UP 72 <.001 0.0045
APOPTOSIS 67 <.001 0.0248
BRENTANI_TRANSCRIPTION_FACTORS 64 <.001 0.0236
UVC_XPCS_ALL_UP 61 <.001 0.0000
UVC_XPCS_8HR_UP 58 <.001 0.0000
UVC_TTD_4HR_UP 58 <.001 0.0020
ET743_HELA_UP 56 <.001 0.0007
CMV_HCMV_6HRS_DN 55 <.001 0.0000
CMV_HCMV_TIMECOURSE_6HRS_DN 52 <.001 0.0007
TPA_SENS_LATE_UP 52 <.001 0.0394
CMV_HCMV_TIMECOURSE_14HRS_UP 45 <.001 0.0000
ZUCCHI_EPITHELIAL_DN 43 <.001 0.0008
TNFALPHA_30MIN_UP 42 <.001 0.0065
EGF_HDMEC_UP 42 <.001 0.0066
ADIP_DIFF_CLUSTER2 40 <.001 0.0002
HYPOXIA_REG_UP 38 <.001 0.0000
DSRNA_UP 38 <.001 0.0002
IFN_GAMMA_UP 38 <.001 0.0014
STRESS_GENOTOXIC_SPECIFIC_UP 34 <.001 0.0045
ST_TUMOR_NECROSIS_FACTOR_PATHWAY 29 <.001 0.0065
OXSTRESS_BREASTCA_UP 29 <.001 0.0071
DAC_BLADDER_UP 28 <.001 0.0046
CMV_UV-CMV_COMMON_HCMV_6HRS_DN 27 <.001 0.0064
IFNALPHA_NL_UP 27 <.001 0.0084
CMV_HCMV_6HRS_UP 25 <.001 0.0010
AD12_ANY_DN 25 <.001 0.0034
IDX_TSA_UP_CLUSTER1 25 <.001 0.0048
The microarray data generated by treating TC32 and TC71 with ET-743 was compared with more
than 1892 curated gene sets using GSEA [36]. All had P < .001 and FDR < 0.05.
The source of the data can be found on the Web site (http://www.broad.mit.edu/gsea/) and is
referenced in the text where appropriate.
Size indicates the number of genes in the gene set that shows overlap with the ones in the expres-
sion data set.
